Alzprotect

• Focused pipeline in high-unmet-need neurodegenerative space (Progressive Supranuclear Palsy) with potential for significant clinical impact
• Early-stage biotech environment offers opportunity to shape drug development strategy and wear multiple hats in a lean organization
• European location provides access to leading neurology research institutions and clinical networks

Generated by Claude from Alzprotect's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.